logo
What to know about UK warning on weight loss drugs' effect on birth control

What to know about UK warning on weight loss drugs' effect on birth control

Yahoo05-06-2025
Regulators in the United Kingdom issued guidance on Thursday, warning that weight loss and diabetes medications may weaken the effectiveness of birth control and may be harmful for pregnant women.
The Medicines and Healthcare products Regulatory Agency (MHRA) said women taking tirzepatide, sold under the brand name Mounjaro, may need to use another form of contraception.
This is because Mounjaro, a medication licensed to treat diabetes and for weight loss management in the U.K. in conjunction with diet and exercise, may reduce the effectiveness of oral contraceptives in those who are overweight.
MORE: Compound versions of GLP-1 drugs for weight loss halted by FDA
The MHRA advised women taking Mounjaro who are overweight and are using an oral form of contraception to also use a non-oral form of contraception, such as a birth control implant, an intrauterine device or condoms.
The agency said using a backup form of birth control is especially important for the four weeks after starting Mounjaro and after any increase in dosage. It also advised taking a second form of birth control for up to two months after taking this class of medications before trying to become pregnant, and recommended against use while pregnant, breastfeeding or trying to become pregnant.
Similarly, the U.S. Food and Drug Administration recommended women on Mounjaro and using oral contraceptives switch to a non-oral form of birth control and use "a barrier method" four weeks after starting use or after a dose increase.
Obstetrics experts told ABC News there have been anecdotal reports of women becoming pregnant while taking tirzepatide -- which falls under a class of medications known as glucagon-like peptide-1 receptor agonists, or GLP-1s -- even though they were on a birth control pill. There are two reasons this may be happening, experts said.
Dr. Elizabeth Langen, an associate professor and maternal-fetal medicine specialist at University of Michigan Health, told ABC News that pregnancy may become more likely in some women after they lose weight.
Additionally, GLP-1s may affect digestion and an oral form of contraception may not be absorbed as effectively, she said.
"Some of these medications change how we digest food and/or medications," Langen said. "It slows that process down, and so we might not have the same blood levels of the hormones that we're expecting to if we're taking an old contraceptive drug, because the weight loss or diabetes medication is impacting our digestion."
MORE: Weight-loss meds may give people more control over drinking, study shows
Dr. Christina Boots, a reproductive endocrinology and infertility specialist at Northwestern Medicine in Chicago, said she's not sure if the recommendation for a backup form of contraception came from data seen during phase I or phase II clinical trials or if researchers saw more incidental pregnancies in those early studies.
She said sexually active patients who are on weight loss medications should speak to their doctor if they're concerned about getting pregnant.
The MHRA also warned that medicines like Mounjaro included Ozempic, Wegovy, Saxenda and Victoza should not be taken during pregnancy, while trying to get pregnant or during breastfeeding.
The agency said this is because there is a lack of safety data on whether taking the medicine could cause harm to a fetus.
Boots said there are no formal guidelines on the use of GLP-1s in pregnancy. Studies done on rodents suggest there could be birth defects and problems with metabolic function, but no large studies have been conducted on humans.
"With these newer weight loss medications, the challenge is basically that we, unfortunately, don't have a lot of data on how they're going to impact fetal development and how they might impact a mom's health during her pregnancy," Langen said
She went on, "There are other means of controlling diabetes [and] weight loss. We tend to favor those because we know that they're safe for both the mom and the fetus during a pregnancy."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Fish Bone or Cancer? 80-Year-Old's Perforation Case
Fish Bone or Cancer? 80-Year-Old's Perforation Case

Medscape

timean hour ago

  • Medscape

Fish Bone or Cancer? 80-Year-Old's Perforation Case

Key Takeaways An 80-year-old man presented with progressive lower left-quadrant abdominal pain. Imaging studies identified a mass adjacent to the sigmoid colon, with features suggestive of an abscess, although no definitive foreign body was detected preoperatively. Surgical exploration revealed a sigmoid colon perforation associated with a sharp foreign object, which was later confirmed to be a fish bone. Histopathological examination revealed an inflammatory response without evidence of malignancy. The case reported by Daniel Herrera Hernández, MD, and colleagues from the Hospital General Regional No. 1 Instituto Mexicano del Seguro Social, Tijuana, Mexico, highlighted a rare cause of intestinal perforation. The Patient and His History The patient had a medical history of diabetes mellitus and hypertension. There was no prior surgical history or screening colonoscopy. He reported a 12-day history of lower left-quadrant abdominal pain, progressively worsening to become intolerable, prompting emergency admission. Findings and Diagnosis On presentation, the patient was stable but exhibited abdominal distension and tenderness on palpation of the left hemiabdomen, without signs of peritoneal irritation. Laboratory tests showed leucocytosis of 20,800/μL (4000-11,000), neutrophils at 65.1% (40%-70%) of total leukocytes, and a serum creatinine of 1.0 mg/dL (0.6-1.2). Abdominal and pelvic CT scans revealed a mass adjacent to the descending colon with peripheral enhancement dependent on the colonic wall, extending into the muscular layer, suggestive of an abscess, as well as a small radio-opaque object in the middle of the phlegmon, supportive of a foreign body. Adjacent fat stranding and free fluid were observed in the left iliac fossa. The patient underwent exploratory laparotomy, revealing a colonic perforation at the sigmoid colon with firm adhesions to the abdominal wall. A sharpened foreign body, approximately 2 cm in length, was found at the adhesion site, which was the cause of the perforation. No diverticula were identified in the colon. Left hemicolectomy with transverse colon terminal colostomy was performed. Postoperative recovery was uneventful under antibiotic therapy with meropenem and metabolic management. The patient was discharged on postoperative day 5 with clinical improvement. The histopathology report indicated chronic inflammation with no evidence of malignancy. Discussion 'Intestinal perforation by a fish bone in the colon is a rare complication that poses diagnostic challenges. It requires a high index of suspicion from surgeons or emergency physicians. In patients with risk factors, such perforations can resemble tumours with abscess formation or perforation secondary to malignancy,' the authors wrote. This story was translated from Univadis Germany.

Why Eli Lilly Stock Popped Today
Why Eli Lilly Stock Popped Today

Yahoo

time4 hours ago

  • Yahoo

Why Eli Lilly Stock Popped Today

Key Points Eli Lilly beat on earnings last week. But then it missed on expectations for the performance of its new orforglipron weight loss drug. This GLP-1 weight loss drug play has a lot more room to run. 10 stocks we like better than Eli Lilly › Shares of Eli Lilly (NYSE: LLY), the pharmaceuticals giant and maker of the Mounjaro and Zepbound weight loss drugs, saw its stock bounce back a modest 2.5% through 1:55 p.m. ET Monday on some positive news out of Wall Street. Specifically: Bernstein says that Eli Lilly stock is a buy. What Bernstein says about Lilly stock Lilly stock got pummeled last week, falling 18% after reporting 38% revenue growth in its second-quarter report. It also reported that its new oral (pill) weight-loss drug orforglipron didn't cut patients' weight quite as much as the company had hoped it would. But according to Bernstein analyst Courtney Breen, this steep decline in stock price has created a "clear buying opportunity" for new investors, as she writes in a note on today. Lilly beat on both sales and earnings last week, notes Breen, and investors' decision to sell off the stock on less-than-stellar orforglipron results "was overblown," subtracting almost $100 billion from Lilly's market capitalization. Tagging the new drug with an affectionate diminutive, Breen argues that "Orfo" can still play a "market expanding role" that will drive Lilly's already strong results even higher in future years. Is Lilly stock a buy? I think she's right about that. Consider: Breen predicts that Lilly will earn $22.84 per share this year, and most analysts agree that the stock can grow earnings 32% or better over the next five years. To get a price/earnings-to-growth (PEG) ratio of 1.0, that would therefore imply a fair value of $730 for Lilly stock -- and right now, Lilly stock costs only $640 and change! At minimum, I'd therefore forecast 14% upside for Lilly stock today. Add in a modest 1% dividend yield, and that makes Lilly stock a buy in my book. Should you buy stock in Eli Lilly right now? Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Eli Lilly Stock Popped Today was originally published by The Motley Fool

Texas AG sues Eli Lilly for allegedly bribing medical providers to prescribe Lilly drugs
Texas AG sues Eli Lilly for allegedly bribing medical providers to prescribe Lilly drugs

Indianapolis Star

time9 hours ago

  • Indianapolis Star

Texas AG sues Eli Lilly for allegedly bribing medical providers to prescribe Lilly drugs

Texas Attorney General Ken Paxton is suing Eli Lilly, alleging the Indianapolis pharmaceutical company offered kickbacks to medical providers in exchange for prescribing more than a dozen of the company's drugs, including blockbuster GLP-1 weight loss drugs Mounjaro and Zepbound. Eli Lilly offered illegal incentives to Texas medical providers, including a "free nurse" program and reimbursement support services, to steer providers to provide the company's drugs, Paxton alleges in a lawsuit filed August 11 in a Texas district court. Lilly, one of the world's largest pharmaceutical companies, denied the allegations in an August 12 statement to IndyStar. The Lilly programs mentioned in the suit offered free trainings for nurses and medical providers, which helped Lilly market their drugs when they launched, the suit says. According to Paxton's office, many Texas residents prescribed these drugs were on state Medicaid, so these actions violated the Texas Health Care Program Fraud Prevention Act. 'Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme,' Paxton said in a news release. 'Eli Lilly fraudulently sought to maximize profits at taxpayer expense and put corporate greed over people's health. I will not stand by while corporations unlawfully manipulate our healthcare system to line their own pockets.' A spokesperson for Eli Lilly said the company denies the allegations and plans to defend against them in court. It's not the first time Paxton has taken a stab at Lilly in the courts. In October, Paxton sued insulin manufacturers and pharmacy benefit managers, including Lilly, Express Scripts and CVS, for allegedly concocting a conspiracy to increase insulin prices. Health Choice Alliance LLC, a New Jersey based company, joined Texas as a plaintiff. Health Choice has sued Lilly in the past, alleging the company engages in kickbacks. 'Multiple courts and the federal government have rejected claims by this same corporate relator against Lilly as meritless," a Lilly spokesperson said in a statement. "In fact, the United States government determined that 'the relators' allegations lack sufficient factual and legal support' in a prior case, explaining that 'federal healthcare programs have a strong interest in ensuring that, after a physician has appropriately prescribed a medication, patients have access to basic product support relating to their medication.' We intend to vigorously defend against these allegations.' At the heart of the Texas lawsuit is a class of drugs named GLP-1s prescribed for diabetes and weight loss. Named for the gut hormone receptor the drug targets, injectable GLP-1s have exploded in popularity since Zepbound hit the market in late 2023. Weight loss drugs: Eli Lilly closer to breakthrough weight loss drug; shares tumble as some question results The kickback lawsuit against Lilly is one way Paxton is protecting Texas patients "from corporate schemes that undermine the integrity of the healthcare system," according to his office.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store